肺癌免疫治疗新进展

肺癌是最常见的恶性肿瘤之一,是世界范围内肿瘤相关性死亡的主要原因.目前肺癌的标准治疗为以铂类药物为基础的双药化疗,但是当肺癌患者病情进展后,治疗选择很有限.于是最近几年人们将关注转向了免疫治疗,免疫治疗包括肿瘤疫苗,PD-1、CTLA-4等节点抑制剂,目前获得的研究数据也支持肺癌的免疫治疗效果.本文回顾肿瘤疫苗及CTLA-4、PD-1等节点抑制药物,评估目前免疫药物在各期临床试验所取得的成果,探讨预测免疫药物疗效的生物标志物,以及今后免疫治疗研究的问题及方向.

New progress in immunotherapy of lung cancer

Lung cancer is one of the most common malignant tumors,is the leading cause of the tumor-related death in the world.The standard therapy is currently the chemotherapeutic regimes with the basis of platinum.If the patients' conditions advance,the choice of thrapy is limitted.In recent years,researchers have paid more attention to immunotherapy,this kind of treatment contains tumor vaccines,programmed death-1(PD-1),cytotoxic T lymphocyte antigen-4 (CTLA-4) and so on.The research data have supported the immunotherapy effect.This article reviews the mechanism of anti-tumor vaccines,PD-1,CTLA-4 inhibitors,shows some results about immunotherapy agents in recent series of clinical trials,discusses the biomarkers for predicting the efficacy of immune drugs,introduces the potential problems and directions of future treatment.